Factors Associated with the Selection of Mutations Conferring Resistance to Protease Inhibitors (PIs) in PI-Experienced Patients Displaying Treatment Failure on Darunavir
暂无分享,去创建一个
Philippe Flandre | Vincent Calvez | Christine Katlama | V. Calvez | C. Katlama | G. Peytavin | Marc Wirden | Gilles Peytavin | C. Blanc | Anne-Geneviève Marcelin | Sidonie Lambert-Niclot | Ana Canestri | Christine Blanc | Rachid Agher | Cathia Soulié | R. Agher | P. Flandre | A. Marcelin | C. Soulié | S. Lambert-Niclot | A. Canestri | M. Wirden
[1] Deenan Pillay,et al. Update of the drug resistance mutations in HIV-1: Fall 2006. , 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[2] Dirk Jochmans,et al. TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates , 2005, Antimicrobial Agents and Chemotherapy.
[3] J. Weber,et al. Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. , 1997, The Journal of antimicrobial chemotherapy.
[4] J. Condra,et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.
[5] V. Calvez,et al. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients , 2004, Journal of medical virology.
[6] C. Petropoulos,et al. Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients , 2000, AIDS.
[7] R. Haubrich,et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients , 2007, AIDS.
[8] Jonathan M. Schapiro,et al. Genotypic Changes in Human Immunodeficiency Virus Type 1 Protease Associated with Reduced Susceptibility and Virologic Response to the Protease Inhibitor Tipranavir , 2006, Journal of Virology.
[9] R. Swanstrom,et al. Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance. , 2000, Pharmacology & therapeutics.
[10] C. Katlama,et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1 , 2007, AIDS.
[11] R. Haubrich,et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials , 2007, The Lancet.
[12] R. Elston,et al. Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside Inhibitors , 2002, Antimicrobial Agents and Chemotherapy.
[13] D. R. Kuritzkes,et al. Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir , 1998, Antimicrobial Agents and Chemotherapy.
[14] Richard A. Rode,et al. Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced Patients , 2001, Journal of Virology.
[15] A. Molla,et al. Recent developments in HIV protease inhibitor therapy. , 1998, Antiviral research.
[16] R. Schooley,et al. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF , 2002, AIDS.
[17] D. Ho,et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir , 1996, Nature Medicine.
[18] P. Kissinger,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.
[19] M. Ott,et al. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. , 1996, The Journal of infectious diseases.
[20] J. Stockman. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials , 2009 .
[21] Tommy F. Liu,et al. HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. , 2005, The Journal of infectious diseases.
[22] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[23] Celia A. Schiffer,et al. Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor , 2004, Journal of Virology.
[24] D. Richman,et al. 2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.
[25] R. Shafer,et al. Genotypic predictors of human immunodeficiency virus type 1 drug resistance , 2006, Proceedings of the National Academy of Sciences.
[26] S. Hammer,et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.
[27] C. Delaugerre,et al. Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients , 2007, AIDS (London).
[28] Amalio Telenti,et al. Update of the drug resistance mutations in HIV-1: Fall 2005. , 2005, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[29] J. Mellors,et al. 3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine , 2000, Annals of Internal Medicine.
[30] A. Molla,et al. Identification and Structural Characterization of I84C and I84A Mutations That Are Associated with High-Level Resistance to Human Immunodeficiency Virus Protease Inhibitors and Impair Viral Replication , 2006, Antimicrobial Agents and Chemotherapy.
[31] A. Molla,et al. Selection of Resistance in Protease Inhibitor-Experienced, Human Immunodeficiency Virus Type 1-Infected Subjects Failing Lopinavir- and Ritonavir-Based Therapy: Mutation Patterns and Baseline Correlates , 2005, Journal of Virology.
[32] L J Davis,et al. Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.